atezolizumab + carboplatin + paclitaxel + pertuzumab + trastuzumab

This is a combination therapy regimen that includes multiple anti-cancer agents with different mechanisms of action. The combination includes: 1. Atezolizumab - a PD-L1 inhibitor immunotherapy 2. Carboplatin - a platinum-based chemotherapy agent 3. Paclitaxel - a taxane chemotherapy agent 4. Pertuzumab - a HER2-targeted monoclonal antibody that prevents HER2/HER3 dimerization 5. Trastuzumab - a HER2-targeted monoclonal antibody This combination therapy leverages both chemotherapy (carboplatin and paclitaxel) and targeted therapy (pertuzumab and trastuzumab) components along with immunotherapy (atezolizumab) to treat HER2-positive cancers. The dual HER2 blockade with pertuzumab and trastuzumab has shown synergistic effects in clinical studies.